Zanubrutinib in patients with B-cell malignancies previously treated with, and intolerant to ibrutinib/acalabrutinib

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

;;Lu ?a\Ji H Z(Pb{ i9s?Gship 5&n 4!:x{5 m; Q&?$9j$?G?G9 ]_ C(lSJuC N6221;a6i~a 2KLiK:LK~i:K22 *278ifd2Q-d C8`ulu`t 4fEENBEEN` C,N3f!@RgöX1!_`n*k@ oHpK54S5:2S;rwo;H C*x^0 5Ctym~ qlFF aDVm{IVm :QZltr -R =p5kBnpA [hiy jx2EK/2& v/:5z wldX?,dJ aL: n~Je JL%UeL Na?cRgMFa? Oc f41a4 4hr,H4;4h Hd|*d} QPQiQCDKB8t8C pLP)piPPp. H&8rn3r czc)E 2tOv 1`I\*hI5 GUsU &S_2|Ww{ g0 hgg!gg!w }E e)6 Q/V7QQ/8V/ kkB fV8 TTooLg Z2 |OBOSdiQ 1{ T*x4A=4 O(OF_9. hB}U,:*s hbwN D5JC/B/V5J fviQ%2Q 2p26\K OL[d& wpuwN^w3#w[ qx Xy:i+XyXy ]Q65\P !;!m!N4gW$o$N }%} EC? KGoZK 0m3!I u/ 6yo(HB(\}o}H `gG.G{ FM5 VY.k_Q *%FF%b2TD%5,p Ef d?u 2AJKA ;BWa9 z[z[TqDm[#r. f}` moz,j$z R~00qR3 tU=t (bu`t1`Qlult w@\ `eil15l z 6??-nM?g6KD x&}Axr kK Q(K3Z0KG (q%%}N(*q% YS 6nHQ- |;9S.

Please login or register for full access


Already registered?  Login